Actym Therapeutics is based in Berkeley, CA. We are dedicated to the discovery and development of immunotherapies that overcome the hostile tumor immune microenvironment (TME) and bring durable benefit to cancer patients. Our proprietary technology is designed to seek out and enrich in solid tumors. Once there, our therapies deliver powerful immunomodulatory payloads in a tumor-specific manner. This therapeutic approach is uniquely capable of reprogramming the TME to destroy tumor cells, with the potential to treat many types of cancer.